Company Reports

Merck KGaA operates in three key segments: healthcare, life science, and electronics. Over the past decade, strategic acquisitions and divestitures have strengthened its position across these industries, broadened its exposure to end markets with stronger long-term growth potential, and supported its competitive advantages.

Merck KGaA operates in three key segments: healthcare, life science, and electronics. Over the past decade, strategic acquisitions and divestitures have strengthened its position across these industries, broadened its exposure to end markets with stronger long-term growth potential, and supported its competitive advantages.

Merck KGaA reported 4.1% organic growth in the second quarter, with strong contributions from the life science and electronics segments. Adjusted EBITDA margin expanded to 29.6% in the first half from 28.5%. Management raised its full-year guidance.

Merck KGaA operates in three key segments: healthcare, life science, and electronics. Over the past decade, strategic acquisitions and divestitures have strengthened its position across these industries, broadened its exposure to end markets with stronger long-term growth potential, and supported its competitive advantages.

Merck KGaA operates in three key segments: healthcare, life science, and electronics. Over the past decade, strategic acquisitions and divestitures have strengthened its position across these industries, broadened its exposure to end-markets with stronger long-term growth potential, and supported its competitive advantages.

On June 25, Merck KGaA announced its plan to acquire Bio-Techne in an all-cash deal at USD 73 per share, valuing it at USD 11.3 billion, a 24% premium to Bio-Techne's prior-day closing price. Investors reacted neutrally, with a slightly positive share price reaction.

Merck KGaA reported strong first-quarter results, ahead of company-compiled consensus. Organic sales growth reached 2.9%, and adjusted EBITDA margin increased to 29.8% from 29.1%. Management raised its guidance, and shares rose 6% in May 13 trading.

Merck KGaA operates in three key segments: healthcare, life science, and electronics. Over the past decade, strategic acquisitions and divestments have strengthened its position in these industries, increasing its exposure to end-markets with stronger long-term growth potential and supporting its competitive advantages.

Life science stocks have been under pressure since late 2022, but with profits expected to rebound in the high single digits in 2026 on average and potentially accelerate even further in 2027-30 due to upcoming catalysts, we see growing momentum in the industry’s profit growth trajectory.

Merck KGaA reported 2.6% organic sales growth in the fourth quarter of 2025, roughly in line with the company-compiled consensus. The full-year sales increased by 3.1%, and adjusted EBITDA reached 28.9%, both of which were in line with management’s guidance. Shares were down 2% intraday.

Merck KGaA operates in three key segments: healthcare, life science, and electronics. Over the past decade, strategic acquisitions and divestments have strengthened its position in these industries, increasing its exposure to end-markets with stronger long-term growth potential and supporting its competitive advantages.

Merck KGaA reported third-quarter earnings with 5.2% organic sales growth, and the adjusted EBITDA margin increased by 70 basis points to 31.4%. Management confirmed its full-year outlook, while narrowing the ranges to approximately 3% organic sales growth and 5%-7% adjusted EBITDA growth.

Merck KGaA reported second-quarter profit lower than the company-compiled consensus. Sales decreased by 2%, influenced by foreign exchange headwinds, which offset organic revenue growth of 2%. Adjusted EBITDA fell by 3.1%. Shares were trading 3% lower intraday after results.

Merck KGaA operates in three key segments: healthcare, life science, and electronics. Over the past decade, strategic acquisitions and divestments have strengthened its position in these industries, increasing its exposure to end-markets with stronger long-term growth potential and supporting its competitive advantages.

Merck KGaA reported its first-quarter 2025 results, with sales and underlying EBITDA growing by 3.2% and 5.6%, respectively—in line with company-compiled consensus estimates. Shares traded 5% lower intraday on May 15, as management slightly lowered its full-year guidance.

Merck KGaA operates in three key segments: healthcare, life science, and electronics. Over the past decade, strategic acquisitions and divestments have strengthened its position in these industries, increasing its exposure to end-markets with stronger long-term growth potential and supporting its competitive advantages.

Merck KGaA announced the acquisition of US biotech firm SpringWorks Therapeutics at an approximate enterprise value of EUR 3 billion. The transaction will be funded through a combination of cash and newly funded debt.

Over the past week, life science shares have experienced significant volatility related to a deepening trade war with China and as broader US tariffs were implemented and then paused for 90 days to allow time for negotiations. A pharmaceutical-specific tariff is also being considered.

After taking a fresh look at Merck KGaA, we are maintaining the company’s narrow moat rating, while adjusting the fair value estimate to EUR 148 from EUR 171.

Merck KGaA operates in three key segments: healthcare, life science, and electronics. Over the past decade, strategic acquisitions and divestments have strengthened its position in these industries, increasing its exposure to end-markets with stronger long-term growth potential and supporting its competitive advantages.